ISOPROPYL ((4-((2-BROMO-(1,1'-BIPHENYL)-3-YL)METHOXY)-5-METHYL-2-(PYRIDIN-3-YLMETHOXY)CYCLOHEXA-2,4-DIEN-1-YL)METHYL)-L-SERINATE
Malignant Neoplasms
Tianjin Chasesun Pharmaceutical Co., LTDSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1412 Active assets in the Malignant Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nabiximols Jazz Pharmaceuticals | Phase 3 | BBB |
Inno-206 M.D. Anderson Cancer Center | Phase 2 | BB |
Vitamin B6 M.D. Anderson Cancer Center | Phase 4 | BB |
PROPOFOL Hong Kong Children's Hospital | Phase 4 | BB |
Rivoceranib Jiangsu HengRui Medicine Co., Ltd. | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →